Minerva Neurosciences, Inc. (NERV)
4.17
+0.05
(+1.21%)
USD |
NASDAQ |
Sep 10, 16:00
4.17
0.00 (0.00%)
After-Hours: 20:00
Minerva Neurosciences Enterprise Value : 190.95M for Sept. 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 09, 2026 | 190.95M |
| September 08, 2026 | 202.76M |
| September 04, 2026 | 205.59M |
| September 03, 2026 | 217.87M |
| September 02, 2026 | 207.95M |
| September 01, 2026 | 207.95M |
| August 31, 2026 | 211.73M |
| August 28, 2026 | 224.95M |
| August 27, 2026 | 238.65M |
| August 26, 2026 | 252.82M |
| August 25, 2026 | 232.51M |
| August 24, 2026 | 223.54M |
| August 21, 2026 | 224.95M |
| August 20, 2026 | 222.59M |
| August 19, 2026 | 222.59M |
| August 18, 2026 | 210.79M |
| August 17, 2026 | 205.12M |
| August 14, 2026 | 212.68M |
| August 13, 2026 | 181.51M |
| August 12, 2026 | 181.51M |
| August 11, 2026 | 200.40M |
| August 10, 2026 | 214.56M |
| August 07, 2026 | 198.03M |
| August 06, 2026 | 206.06M |
| August 05, 2026 | 201.81M |
| Date | Value |
|---|---|
| August 04, 2026 | 187.17M |
| August 03, 2026 | 183.87M |
| July 31, 2026 | 184.34M |
| July 30, 2026 | 186.23M |
| July 29, 2026 | 189.53M |
| July 28, 2026 | 198.51M |
| July 27, 2026 | 194.96M |
| July 24, 2026 | 187.17M |
| July 23, 2026 | 206.54M |
| July 22, 2026 | 205.59M |
| July 21, 2026 | 207.95M |
| July 20, 2026 | 202.76M |
| July 17, 2026 | 198.03M |
| July 16, 2026 | 195.20M |
| July 15, 2026 | 200.40M |
| July 14, 2026 | 186.23M |
| July 13, 2026 | 198.03M |
| July 10, 2026 | 219.29M |
| July 09, 2026 | 219.29M |
| July 08, 2026 | 214.56M |
| July 07, 2026 | 221.65M |
| July 06, 2026 | 228.73M |
| July 02, 2026 | 237.23M |
| July 01, 2026 | 239.59M |
| June 30, 2026 | 258.49M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.882B |
| Alnylam Pharmaceuticals, Inc. | 34.18B |
| Anika Therapeutics, Inc. | 266.28M |
| Savara, Inc. | 969.61M |
| Vericel Corp. | 1.927B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 17.47M |
| Total Expenses (Quarterly) | -17.47M |
| EPS Diluted (Quarterly) | -0.1379 |
| Earnings Yield | -692.4% |
| Normalized Earnings Yield | -234.82 |